Investigation of efficacy and safety of lanthanum carbonate in hyperphosphatemia patients treated with cinacalcet hydrochloride

Investigation of efficacy and safety of lanthanum carbonate in hyperphosphatemia patients treated with cinacalcet hydrochloride - Investigation of efficacy and safety of lanthanum carbonate in hyperphosphatemia patients treated with cinacalcet hydrochloride

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002481

Enrollment

Registered

2009-09-11

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperphosphatemia patients treated with cinacalcet hydrochloride for secondary hyperparathyroidism

Interventions

Treatment of hyperphosphatemia with lanthanum carbonate for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hemodialysis pts 2) Secondary hyperparathyroidism pts treated with cinacalcet 3) Sevelamer monotherapy failure, sevelamer combined with calcium carbonate treatment failure (P > 6.0 mg/dL) or poor compliance of sevelamer

Exclusion criteria

Exclusion criteria: 1)Pts who meet the contraindiation criteria in package insert of lanthanum carbonate 2)Pregnant or possibly pregnant pts, pts on lactation 3)Inappropriate pts for this study according to the investigator's judgment

Design outcomes

Primary

Measure	Time frame
Serum phosphate level	—

Secondary

Measure	Time frame
1. Corrected serum calcium, serum calcium phosphorus product, intact PTH 2. Adverse events 3. Drug compliance	—

Countries

Japan

Contacts

Public ContactKatsuhiko Arimoto

Shigei medical research hospital Internal medicine, institute of kidney disease

086-282-5311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026